Giulio Francesco Gramaglia

Dr. Giulio Francesco Gramaglia

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
MLMichele Lombardo
Michele Lombardo
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
ALAlessandro Lucidi
Alessandro Lucidi
SHSergio Harari
Sergio Harari
Background: Prognostic heterogeneity in heart failure (HF) is substantial and not fully captured by conventional left-sided echocardiographic parameters. Growing evidence highlights the importance of right ventricular–pulmonary arterial (RV–PA) interaction in HF pathophysiology and outcomes. The echocardiographic tricuspid annular plane systolic excursion-to-systolic pulmonary artery pressure (TAPSE/sPAP) ratio has been proposed as a simple noninvasive surrogate of RV–PA coupling, yet its prognostic value across the HF spectrum remains incompletely defined. Methods: This systematic review followed PRISMA guidelines and was registered in INPLASY. PubMed, Scopus, and EMBASE were searched from inception through January 2026 for observational studies evaluating the prognostic value of TAPSE/sPAP in adult patients with HF. Study selection, data extraction, and risk-of-bias assessment were performed independently by two reviewers. Owing to substantial heterogeneity, a qualitative synthesis with weighted pooled descriptive statistics was performed. Results: Fifteen observational studies including 5389 patients were analyzed, with a median follow-up of approximately 1.9 years, ranging from in-hospital outcomes to long-term follow-up of up to 15 years. Study populations encompassed a wide range of HF phenotypes and clinical settings, including acute and chronic HF, preserved and reduced ejection fraction, valvular heart disease, infiltrative cardiomyopathies, and advanced HF. Across studies, reduced TAPSE/sPAP was generally associated with adverse outcomes, including all-cause mortality and HF-related events, with reported hazard ratios ranging from approximately two- to five-fold. Prognostically relevant TAPSE/sPAP cut-off values tended to cluster within a relatively narrow range, with most thresholds between 0.36 and 0.40 and a weighted median of approximately 0.36. When reported, TAPSE/sPAP showed favorable discriminative performance for adverse outcomes. Overall methodological quality was predominantly fair. Conclusions: Across heterogeneous HF populations, impaired TAPSE/sPAP appears to be a consistent marker of adverse prognosis. These findings support TAPSE/sPAP as a practical, noninvasive indicator of RV–PA uncoupling that may contribute to risk stratification and phenotyping in heart failure. Prospective studies focusing on specific HF phenotypes are needed to clarify its role in longitudinal monitoring and therapeutic decision-making.

21 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
MBMassimo Baravelli
Massimo Baravelli
MLMichele Lombardo
Michele Lombardo
Background: Epicardial adipose tissue (EAT) is a metabolically active visceral fat depot increasingly associated with the development and progression of coronary artery disease (CAD). Transthoracic echocardiography is the most widely used modality for EAT assessment; however, substantial heterogeneity exists regarding the timing of measurement within the cardiac cycle, with EAT thickness variably assessed during systole or diastole. Whether these measurements provide equivalent information for identifying obstructive CAD remains unclear. This systematic review and meta-analysis evaluated the association between echocardiographically measured EAT thickness and angiographically confirmed obstructive CAD, with specific focus on systolic versus diastolic assessments. Methods: PubMed, Scopus, and EMBASE were systematically searched through December 2025 for observational studies comparing EAT thickness in patients with and without obstructive CAD confirmed by invasive coronary angiography. Random-effects models were used to pool standardized mean differences (SMDs) for systolic and diastolic EAT thickness. Heterogeneity was assessed using the I2 statistic, publication bias by funnel plots and Egger’s regression test, and robustness by meta-regression and leave-one-out sensitivity analyses. Results: Twenty-two studies including more than 6500 patients were analyzed. Both systolic and diastolic EAT thickness were significantly greater in patients with obstructive CAD than in non-CAD controls. Systolic EAT showed a large, pooled effect size (SMD 1.27; 95% CI 0.96–1.59; p < 0.001), while diastolic EAT demonstrated a similarly strong association (SMD 1.59; 95% CI 1.10–2.07; p < 0.001). Heterogeneity was substantial (I2 > 90%), but the direction of effect was consistent across all studies. Meta-regression analyses indicated that demographic, clinical, metabolic, geographic, and methodological characteristics, including ultrasound software/vendor category and timing of EAT measurement, did not significantly moderate the association between EAT thickness and obstructive CAD. No significant publication bias was detected, and sensitivity analyses confirmed the robustness of the results. Conclusions: Echocardiographically measured EAT thickness is strongly and consistently associated with obstructive CAD, irrespective of whether measurements are obtained during systole or diastole. Although both approaches show robust discriminatory capacity at the population level, differences in effect magnitude suggest that they may not be fully interchangeable. Moreover, in the absence of standardized and broadly applicable cut-off values, the interpretation and clinical management of EAT measurements as individual risk predictors require further investigation.

24 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
MBMassimo Baravelli
Massimo Baravelli
MLMichele Lombardo
Michele Lombardo
Background: Relative apical sparing of longitudinal strain is widely used as a diagnostic marker of cardiac amyloidosis. However, similar deformation patterns have been reported in other cardiac diseases, raising concerns regarding disease specificity. A comprehensive multimodality synthesis of the relative apical sparing pattern (RASP) across disease entities is lacking. Methods: A systematic review and meta-analysis were conducted according to PRISMA guidelines. PubMed, Scopus, and EMBASE were searched through December 2025 for studies reporting RASP or regional longitudinal strain values allowing standardized RASP calculation. Cardiac amyloidosis and major phenocopies—including aortic stenosis, hypertrophic cardiomyopathy, hypertensive heart disease, Fabry disease, mitral valve prolapse, and other cardiomyopathies—were included. Random-effects models were used to compare cardiac amyloidosis with non-amyloid conditions using standardized mean differences (SMDs), with subgroup analyses according to imaging modality (two-dimensional speckle-tracking echocardiography [2D-STE] versus cardiac magnetic resonance feature tracking [CMR-FT]). Results: Fourteen studies (nine 2D-STE and five CMR-FT) were included in the quantitative synthesis. Overall, cardiac amyloidosis was associated with significantly higher RASP compared with non-amyloid conditions (SMD 0.676, 95% CI 0.493–0.860; p < 0.001), with substantial heterogeneity (I2 = 96.9%). Modality-stratified analyses showed a very large pooled effect for 2D-STE (SMD 2.152, 95% CI 1.354–2.950; I2 = 97.6%) and a moderate, homogeneous effect for CMR-FT (SMD 0.594, 95% CI 0.405–0.782; I2 = 0%). Sensitivity analyses confirmed robustness. No significant publication bias was detected by Egger’s test. Conclusions: Relative apical sparing is not specific to cardiac amyloidosis but is most pronounced in this condition. Its diagnostic magnitude varies across modalities and clinical contexts, supporting a multiparametric, modality-specific interpretation.

24 April 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
MLMichele Lombardo
Michele Lombardo
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
MBMassimo Baravelli
Massimo Baravelli
Background: Risk stratification of patients with asymptomatic aortic stenosis (AS) remains challenging, as symptom-based assessment may underestimate disease severity. Exercise stress echocardiography (ESE) provides a comprehensive evaluation of valvular, ventricular, and cardiopulmonary responses under physiological stress and may improve prognostic assessment. Methods: A systematic review was conducted according to PRISMA guidelines to evaluate the prognostic value of ESE in asymptomatic moderate and severe AS. Electronic databases (PubMed, Scopus, and EMBASE) were searched from inception to March 2026. Studies were included if they assessed adult patients with asymptomatic moderate or severe AS undergoing exercise-based stress echocardiography and reported clinical outcomes. Studies using exclusively pharmacological stress or lacking outcome data were excluded. Data were extracted and synthesized qualitatively. Continuous variables were summarized as weighted medians and interquartile ranges. Results: A total of 11 studies were included, encompassing a heterogeneous population of patients with moderate-to-severe and severe AS. During follow-up, a substantial proportion of patients experienced adverse events, including symptom onset, aortic valve replacement, or death. Across studies, exercise-derived parameters consistently showed strong prognostic value. In particular, exercise-induced increases in mean transvalvular gradient, an elevated E/e’ ratio, the development of pulmonary hypertension, and reduced functional capacity emerged as the most reproducible predictors of adverse outcomes. Notably, thresholds such as an increase in mean transvalvular gradient ≥ 18–20 mmHg, peak exercise E/e’ ≥ 15, and systolic pulmonary artery pressure ≥ 60 mmHg were consistently associated with a higher risk across multiple studies. Myocardial deformation parameters and biomarkers such as exercise-induced BNP further contributed to risk stratification in selected studies. In contrast, resting parameters alone were less consistently predictive. Conclusions: ESE provides incremental prognostic information in asymptomatic moderate and severe AS by unmasking subclinical hemodynamic and myocardial abnormalities. The integration of stress-derived parameters, including reproducible threshold values, into clinical assessment may improve risk stratification and support more individualized management strategies. Further studies are needed to validate these cut-offs and define their role in guiding clinical decision-making.

1 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
MBMassimo Baravelli
Massimo Baravelli
MLMichele Lombardo
Michele Lombardo
Background: The association between mitral valve prolapse (MVP) and anxiety disorders has remained controversial for more than four decades because of heterogeneous psychiatric definitions, evolving echocardiographic diagnostic criteria, and conflicting findings across observational studies. We performed a systematic review to examine the available evidence in both directions of the MVP–anxiety relationship, together with a meta-analysis of anxiety-related outcomes among patients with MVP versus controls, and to evaluate the influence of different echocardiographic diagnostic criteria on this association. Methods: PubMed, Scopus, and EMBASE were systematically searched for observational studies evaluating either direction of the association between MVP and anxiety disorders. Studies assessing anxiety-related outcomes in patients with MVP or the prevalence of MVP among individuals with anxiety disorders were included in the systematic review. Quantitative synthesis was restricted to studies providing comparative data on dichotomous anxiety-related outcomes in MVP and control populations, using random-effects models to calculate pooled odds ratios (ORs) with 95% confidence intervals (CIs), whereas evidence concerning MVP prevalence among individuals with anxiety disorders was synthesized descriptively. Results: Seventeen studies published between 1979 and 2026 met the inclusion criteria, including 10 evaluating anxiety-related outcomes in patients with MVP and 7 assessing MVP prevalence among patients with anxiety disorders. Eight studies evaluating anxiety-related outcomes in MVP versus control populations were eligible for quantitative synthesis, whereas studies examining MVP among individuals with anxiety disorders contributed to the descriptive synthesis. Overall, patients with MVP showed a significantly higher prevalence of anxiety-related outcomes than controls (OR 1.78, 95% CI 1.15–2.75; p = 0.010), with no evidence of between-study heterogeneity (I2 = 0%). The association was significant in studies using 2D echocardiographic assessment but not in those using historical M-mode criteria, with no significant between-subgroup difference (p = 0.227). Meta-regression identified no significant influence of publication year, age, or sex on the pooled estimate. Sensitivity analyses showed that the pooled association was not disproportionately influenced by any single study. Conclusions: Patients with MVP exhibit a significantly increased prevalence of anxiety-related outcomes compared with controls, although no causal relationship or effect modification by echocardiographic method can be established. Conversely, evidence on MVP prevalence among individuals with anxiety disorders remains heterogeneous and currently supports only descriptive synthesis. Future prospective studies integrating standardized psychiatric assessment, contemporary echocardiographic criteria, and quantitative thoracic morphometry are warranted to clarify the underlying mechanisms and clinical implications.

21 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Andrea SonaglioniAndrea Sonaglioni
Andrea Sonaglioni
GGGiulio Francesco Gramaglia
Giulio Francesco Gramaglia
EMElena Mondazzi
Elena Mondazzi
Gian Luigi NicolosiGian Luigi Nicolosi
Gian Luigi Nicolosi
MLMichele Lombardo
Michele Lombardo
MBMassimo Baravelli
Massimo Baravelli
Background: Asymptomatic atrial fibrillation (AF) is increasingly recognized through incidental diagnosis and continuous rhythm monitoring, yet its clinical phenotype and prognostic significance remain incompletely characterized. We systematically evaluated factors associated with asymptomatic AF and its clinical outcomes. Methods: This systematic review was conducted according to PRISMA 2020 recommendations. PubMed/MEDLINE, Scopus, and EMBASE were searched from inception through 1 September 2026. Studies reporting demographic, clinical, anthropometric, laboratory, electrocardiographic, imaging, or therapeutic correlates of asymptomatic AF and/or associated clinical outcomes were eligible. Given substantial clinical and methodological heterogeneity, evidence was synthesized using structured qualitative analyses and descriptive summaries of study-level data, without formal meta-analysis or inferential testing of aggregated between-group differences. Results: Twenty-three studies were included, comprising 47,456 patients with asymptomatic or subclinical AF and 126,894 participants in the corresponding comparator groups. Study-specific evidence identified male sex, lower ventricular rate, and long-standing persistent or permanent AF as relevant correlates of asymptomatic presentation. Greater left atrial remodeling, including larger atrial dimensions and impaired mechanical function, was also reported in selected studies of silent AF, whereas conventional left ventricular structure and systolic function showed relatively similar descriptive estimates across the available datasets. Selected studies identified metabolic biomarkers and thoracic morphology as additional potential correlates. Rhythm-control strategies and catheter ablation showed numerically lower utilization in descriptive summaries of asymptomatic AF, although the contributing populations were heterogeneous and not necessarily directly comparable. Prognostic findings were heterogeneous: mortality and thromboembolic outcomes were generally comparable between asymptomatic and symptomatic AF in several individual studies, whereas other investigations reported a greater burden of heart failure and heart failure-related events among symptomatic patients. Conclusions: Asymptomatic AF represents a heterogeneous clinical phenotype rather than a benign form of the arrhythmia. A lower ventricular response may attenuate symptom perception, while atrial remodeling and cardiovascular risk may progress despite the absence of symptoms. Symptom status should therefore not replace established cardiovascular risk assessment. Thoracic geometry may represent an additional determinant of symptom perception, although current evidence remains preliminary and requires prospective validation.